Advertisement
UK markets closed

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     

  • CRUDE OIL

    79.24
    +0.86 (+1.10%)
     

  • GOLD FUTURES

    2,316.70
    -7.50 (-0.32%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • Bitcoin GBP

    49,316.62
    -1,103.94 (-2.19%)
     

  • CMC Crypto 200

    1,309.34
    +14.67 (+1.13%)
     

  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     

  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     
Money:

How to make a tax-free income

Tips for making money that won't be taxed

Novartis lung drug not inferior to GSK's Seretide, study shows

Reuters - UK Focus

(Removes paragraph on QVA149, which refers to Ultibro Breezhaler not Onbrez Breezhaler)

ZURICH, April 25 (Reuters) - Patients taking Novartis (Xetra: NOT.DE - news) ' inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline (Other OTC: GLAXF - news) 's Seretide, the Swiss drugmaker said on Friday, citing a late stage study.

The Phase IV study in patients with moderate chronic obstructive pulmonary disease (COPD) found Novartis' once-daily drug showed similar benefits in reducing shortness of breath as GSK's Seretide, which must be taken twice daily.

Around 210 million people worldwide suffer from COPD, a disease that causes breathing trouble and chronic coughing, and is sometimes fatal. (Reporting by Caroline Copley; Editing by Edwina Gibbs and Jane Baird)